AVBCC 2013 3rd Annual Conference Abstracts

Perspectives of Quality Care in Cancer Treatment: A Review of the Literature

Lisa M. Hess, PhD; Gerhardt Pohl, PhD

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Although information about quality care is increasingly available, there remains a gap in knowledge regarding stakeholders’ perceptions of quality cancer care. It is important to maintain high quality of patient care, but perspectives of quality may differ by stakeholder.

Objective: This systematic qualitative literature review was conducted to understand the current perceptions of key stakeholders about quality cancer care.

[ Read More ]

Is Oral Electrolyte Replacement More Effective than IV Replacement in the Oncology Population?

Rebecca Martin, BSN, RN, OCN; Joanne Growney, RN, MA, ANP-BC

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Electrolyte abnormalities are the most common laboratory findings in patients with malignancies. Clinical manifestations of several electrolyte deficiencies occur with frequency in malignancy (Hawthorne JL, Schneider SM, Workman ML). Patients who are admitted for chemotherapy regimens as well as for complications post chemo receive electrolyte replacements on a daily basis. Experience has shown consistent patient and staff nurse dissatisfaction with the current replacement protocol. [ Read More ]

Cost Considerations for New Oral Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously

Lorie A. Ellis; Zoe Clancy; R. Scott McKenzie; Mekre’ Senbetta

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Two oral agents for mCRPC patients who previously received docetaxel were recently approved by the US Food and Drug Administration—abiraterone acetate plus prednisone (AA+p) and enzulatamide (EN). Phase 3 studies in this population showed median treatment duration of 8 months for AA+p1 and 8.3 months for EN,2 while median survival was 15.81 months and 18.42 months, respectively. The budgetary impact of these products to payers depends, in part, upon real world treatment duration and the proportion of mCRPC patients utilizing each product.

[ Read More ]

Cost Analysis of Bortezomib Retreatment Compared with Switching to Carfilzomib in Patients with Relapsed Multiple Myeloma Previously Treated with Bortezomib

Kevin B. Knopf, MD, MPH; Marie-Hélène Lafeuille, MA; Jonathan Gravel, MS; Patrick Lefebvre, MA; Liviu Niculescu, MD; Abbie Ba-Mancini, MBA; Esprit Ma, MPH; Mei Sheng Duh, MPH, ScD

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: In an era of multiple effective treatment options for relapsed/refractory multiple myeloma (MM), a recent meta-analysis has shown that retreatment with bortezomib continues to be an effective option in previously treated patients who relapsed. As economic pressures rise in oncology, it is important to evaluate the cost-effectiveness of newer therapies relative to standards of care. Carfilzomib was recently approved by the US Food and Drug Administration for the treatment of relapsed/refractory MM.

[ Read More ]

Imatinib Can Still Be Used as 1st-Line for Treating Chronic Myelogenous Leukemia

Wesley Wong, PhD

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: The introduction of tyrosine kinase inhibitors (TKIs) into clinical practice resulted in a very dramatic prolongation of survival for most, but not all patients with chronic myeloid leukemia (CML) in chronic phase. If properly managed, and if adherence is greater than 80%, the 10-year survival rate reaches 85% for patients treated with the 1st-generation (Gen) TKI, imatinib (Gleevec). Currently, there are five TKIs available for CML. Clinicians must weigh the relative advantages and toxicities of each when selecting a course of treatment. [ Read More ]

Wait Time and Patient Satisfaction—Improving Outcomes Can Be as Easy as Child’s Play

Julia Whiteker; Ann Bredensteiner

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Breast Care at IU Health North Hospital is a multidisciplinary clinic comprised of breast surgeons, medical and radiation oncologists, plastic surgeons and geneticists. It has consistently achieved excellent patient satisfaction scores; however, one area needing improvement was in office wait time. [ Read More ]

Say Ahh! Making Sense of Oral Assessments for Mucositis

Joanne Growney, MA, RN, ANP-BC, OCN; Rebecca Martin, BSN, RN, OCN; Phyllis McKiernan, RN, MSN, APN-BC; Joan Collela, RN, DNP, APN-BC, NP-C; Claudia Douglas, RN, MA, CNN, APN-C

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Chemotherapy and radiation therapy, the mainstays of current cancer treatment, often result in devastating side effects involving the oral cavity. Mucositis, an inflammatory and/or ulcerative lesion of the oral and/or gastrointestinal tract is a common therapy-related toxicity. Mucositis significantly impacts patients’ overall physical and functional well-being, as well as quality of life. [ Read More ]

Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia

Gluck S; Yardley D; Belk K; Craver C; Cox D; Faria C; University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Tennessee Oncology, PLLC, Nashville, TN; MedAssets, Inc., Charlotte, NC; Eisai Inc., Woodcliff Lake, NJ

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Eribulin mesylate (EM) is a microtubule inhibitor shown to improve survival in patients with metastatic breast cancer (MBC) who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. A common grade 3/4 toxicity of EM is neutropenia which may result in dose adjustments and dose delays. To minimze neutropenic complications, granulocyte colony-stimulating factor (GCSF or GMCSF) may be utilized, as well as dose modifications or treatment discontinuation. [ Read More ]

Impact of Treatment Modification on Treatment Duration in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Introduction: EM is a microtubule inhibitor shown to improve overall survival in metastatic breast cancer patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. There are side effects of EM, including neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. While some physicians discontinue treatment due to side effects, others manage side effects using dose delays/skipped doses and/or dose modifications. [ Read More ]

An Assessment of Racial Differences in Toxicities and Supportive Care in Patients with Metastatic Breast Cancer (MBC)

George Dranitsaris; Nancy Beegle; Traci Kalberer; Zhixiao Wang; Claudio Faria; Sibel Blau

March 2013, Vol 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts

Background: Racial disparities in clinical outcomes between Caucasian and African American (AA) MBC patients have been identified. Some of these disparities may be attributed to differences in toxicities and access to supportive care interventions. In this study, treatment toxicities and use of supportive care were compared between Caucasian and AA MBC patients treated in 15 community oncology practices across the United States.

[ Read More ]